It is one of the first questions patients ask me, and it deserves a straight answer: does insurance cover therapeutic plasma exchange (TPE)? The honest reply is that it depends, mostly on why you need it, what kind of plan you have, and where you are treated. For some conditions, coverage is routine. For others, it takes good documentation and some persistence. And at most outpatient apheresis centers, including the one I work with, the billing itself works differently than you might expect. Here is how I walk patients through all of it.

The short version

  • Usually covered: when TPE is an accepted treatment for your diagnosis and your physician documents that it is medically necessary.
  • Case by case: conditions where the evidence is still developing. Approval is possible but not automatic, and sometimes only partial.
  • Generally not covered: elective, wellness, or longevity use.
  • A separate question entirely: how you are billed, which depends on whether your center is in-network or cash-pay.

How insurers actually decide: medical necessity and the ASFA categories

Insurers approve treatments they consider medically necessary for your specific diagnosis. For apheresis, both clinicians and insurers lean heavily on the categories published by the American Society for Apheresis (ASFA), which grade how well-established TPE is for a given condition:

  • Category I: apheresis is accepted as first-line therapy, alone or alongside other treatments.
  • Category II: apheresis is accepted as second-line therapy.
  • Category III: the optimal role is not yet established, so the decision should be individualized.
  • Category IV: the published evidence suggests apheresis is ineffective or harmful.

In practice, Category I and Category II indications are the ones insurers cover most reliably, provided the medical necessity is documented. Examples range from first-line (Category I) indications such as Guillain-Barre syndrome to second-line (Category II) indications such as an acute multiple sclerosis relapse, where TPE is well established when high-dose steroids alone are not enough.

Category III is where it gets nuanced. Coverage is not guaranteed, decisions are made case by case, and approval often comes down to the strength of your documentation and your willingness to appeal. I have seen Category III claims approved, and I have seen plans agree to pay a portion even when they would not approve the full amount. It is genuinely individual. Category IV indications are essentially never covered.

Why most outpatient apheresis centers are cash-pay

Here is the part that surprises people. Hospital-based programs usually bill insurance directly, because the TPE they perform tends to be for acute, inpatient, Category I emergencies. Dedicated outpatient apheresis centers operate differently. Global Apheresis, like most strictly outpatient centers, runs on a cash-pay basis: you pay for the procedure up front, and the center provides you with a superbill so you can seek reimbursement from your insurer yourself.

This is standard for outpatient apheresis, and it is not a signal that a treatment lacks legitimacy. It reflects how these centers are structured and the decision to remain out-of-network. The practical upshot is that, in most cases, getting reimbursed is something you pursue with your plan after the fact, rather than something the center handles before you are treated.

How to seek reimbursement

This is the part worth getting right, because it is where most of the money is won or lost.

1. Get your superbill. This is an itemized receipt your insurer needs to process an out-of-network claim. It lists the procedure, typically billed under CPT code 36514 (therapeutic plasma exchange), along with the diagnosis code for your condition. Ask for it, and keep a copy.

2. Get a letter of medical necessity. For anything beyond the clear-cut Category I cases, this is the single most important document. In my experience the strongest letter comes from the physician who diagnoses and manages your condition, your neurologist, rheumatologist, or other treating specialist, because they can speak to your full clinical picture and explain why TPE is necessary for you specifically. As the apheresis provider, I am always willing to write a supporting letter as well, and sometimes both letters together carry more weight than either alone. Whatever it takes to do right by the patient.

3. Submit, and if you are denied, appeal. A first denial is common and is not the end of the road. A well-built appeal, including the medical necessity letter, your relevant records, and the ASFA category for your indication, frequently changes the result. Even a partial reimbursement can be meaningful.

4. Keep everything. Dates, codes, letters, denial notices, and call logs. Documentation is what carries an appeal.

California families: the new PANDAS and PANS law

If you are in California and seeking TPE for a child with PANDAS or PANS, there is a recent and important change. Assembly Bill 2105 was signed on September 28, 2024 and took effect January 1, 2025. It requires California-regulated health plans and insurance policies (issued, amended, or renewed on or after that date) to cover the prophylaxis, diagnosis, and treatment of PANDAS and PANS when it is ordered by the treating physician and is medically necessary. The law also bars plans from imposing higher cost-sharing than they apply to other benefits, and from denying or delaying coverage simply because a child was previously treated or was diagnosed under a different name. For billing, the law directs that PANDAS and PANS be coded as autoimmune encephalitis until specific codes are created.

Why this matters for apheresis: TPE is a recognized second-line (ASFA Category II) treatment for PANDAS and PANS exacerbations. So for a California child whose treating physician determines that TPE is medically necessary, this law meaningfully strengthens the case for coverage.

One important caveat. The mandate applies to California-regulated plans, which covers most fully insured policies. It does not reach self-funded employer plans, which are governed by federal law and sit outside a state requirement. If you are not sure which kind of plan you have, your HR department or plan documents can tell you, and it is worth confirming before you build your expectations around the law.

What insurance generally will not cover

I want to be candid about the other side of this. When TPE is sought for general wellness, longevity, anti-aging, or similar elective reasons rather than an accepted medical indication, insurers virtually never cover it. If that is your goal, plan to pay out of pocket. It is better to know that going in than to be surprised by a denial later.

Frequently asked questions

Is TPE covered by insurance? Often yes for established (Category I and II) medical indications when documented as medically necessary, case by case for Category III, and generally no for elective or longevity use.

How many sessions will insurance cover? That depends on your diagnosis, your physician's documentation, and your specific plan. Coverage is tied to medical necessity rather than a fixed number.

What if my center does not take insurance? Most outpatient centers are cash-pay. You pay up front, receive a superbill, and submit it to your insurer for possible reimbursement.

Does insurance cover plasma exchange for longevity or anti-aging? No. Elective and wellness use is not considered medically necessary and is paid out of pocket.

Can a denial be appealed? Yes, and it often should be. First denials are common, and a documented appeal with a medical necessity letter frequently succeeds or results in partial payment.

This article is general information, not a guarantee of coverage or financial or legal advice. Coverage depends on your individual diagnosis, your specific plan, and your state. Always verify benefits directly with your insurer before treatment.

To discuss whether therapeutic plasma exchange is appropriate for your situation and how billing works, reach out through Global Apheresis.